TerminatedPhase 2NCT03562416

Continuation of Nintedanib After Single Lung Transplantation in IPF Subjects

Studying Idiopathic pulmonary fibrosis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Temple University
Principal Investigator
Jonathan A Galli, MD
Temple University
Intervention
Nintedanib(drug)
Enrollment
1 enrolled
Eligibility
35-70 years · All sexes
Timeline
2019 – 2021

Study locations (1)

Collaborators

Boehringer Ingelheim

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03562416 on ClinicalTrials.gov

Other trials for Idiopathic pulmonary fibrosis

Additional recruiting or active studies for the same condition.

See all trials for Idiopathic pulmonary fibrosis →

← Back to all trials